Adie syndrome

Sharma, Rohit; Gaillard, Frank

doi:10.53347/rid-5507

Cited by 3 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic resonance imaging scans may be useful to exclude other conditions that can mimic or cause Adie's tonic pupil. 7 After thorough ophthalmological and neurological examinations, we found no abnormalities suggesting an oculomotor nerve palsy in this patient.…”

Section: Discussionmentioning

confidence: 61%

“…Most patients with Adie's tonic pupil do not require any treatment. 7 Patients with an underlying systemic cause should have treatment directed at their other autonomic neuropathies. The treatment for impairment of the eyes (due to accommodative paresis) is to prescribe reading glasses.…”

Section: Discussionmentioning

confidence: 99%

“…It is caused by damage to the ciliary ganglion or short ciliary nerves (postganglionic parasympathetic nerve injury produces an Adie tonic pupil. 7 Approximately 70% of patients are women 20-40 years of age and tonic pupils are unilateral in 80% of cases. 8 Pharmacological testing can be used to confirm the diagnosis of Adie's tonic pupil.…”

Section: S Case Reportmentioning

confidence: 99%

See 2 more Smart Citations

Unilateral Adie’s Tonic Pupil after Coronavirus Disease-19 (COVID-19): A Case Report

Candella¹

2023

View full text Add to dashboard Cite

Introduction: Adie’s tonic pupil is a neuro ophthalmological disorder characterized by dilated pupil, which is unresponsive to light. It is caused by damage to postganglionic fibers of the parasympathetic innervation of the eye. Recent events of the coronavirus disease 2019 (COVID-19) pandemic had suggested that severe acute respiratory syndrome coronavirus-2 infection (SARS-CoV-2) had neurotropic and neuroinvasive capabilities. Purpose: To report a rare case of unilateral Adie’s tonic pupil after COVID-19. Methods: A single case report study. Case Report: A 31-year-old woman presented with a glare on the right eye 3 months ago. No other symptom was reported. No prior history of using any eye drops and trauma. Further investigation revealed a history of asymptomatic SARS CoV-2 infection. Her best-corrected visual acuity of both eyes was 1.0, but we observed an impairment of accommodation on the right eye. A fixed dilated right pupil, 8 mm in diameter, was observed without any constriction on near reflex. Slit lamp and funduscopy examination were within normal limits on both eyes. Pilocarpine 0.1% test was positive on the right eye. Neurological examinations and brain imaging was within normal limits. The patient was diagnosed with Adie’s tonic pupil. She was treated with pilocarpine 0.1% once daily. After 2 months of follow up, her complaint of glare was diminished but no improvement of near acuity was seen on the right eye. Conclusions: This case report was one of the first few cases of Adie’s tonic pupil possibly associated with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: S Case Reportmentioning

confidence: 99%

See 1 more Smart Citation

Unilateral Adie’s Tonic Pupil after Coronavirus Disease-19 (COVID-19): A Case Report

Candella¹

2023

View full text Add to dashboard Cite

show abstract

“…Adie’s tonic pupil is a result of damage to the ciliary ganglion or short ciliary nerves and might appear due to an infection, trauma, ischemia, or as a result of surgical procedures [ 34 , 35 ]. Patients are likely to develop progressive miosis, bilateral affection (4% each year), and gradual loss of deep tendon reflexes [ 36 , 37 ]. A case of concurrent tonic pupil and trochlear nerve palsy in a patient with the disease was reported by Ordás et al A 62-year-old man described his 5-day history of binocular vertical diplopia and blurred vision in the left eye, with an additional dilatation of the left pupil.…”

Section: Anterior Segment Of the Eyementioning

confidence: 99%

How Does SARS-CoV-2 Affect Our Eyes—What Have We Learnt So Far about the Ophthalmic Manifestations of COVID-19?

Baj

Forma

Teresińska

et al. 2022

JCM

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has become a worldwide threat resulting in a pandemic in 2020. SARS-CoV-2 infection manifests itself as coronavirus disease 2019 (COVID-19) that is evidenced in a vast number of either specific or nonspecific symptoms. Except for typical (but nonspecific) symptoms such as fever, dry cough, or muscle weakness, the infected patients might also present atypical symptoms including neurological, dermatological, or ophthalmic manifestations. This paper summarizes the current state of knowledge regarding the onset, progression, and types of ophthalmic symptoms induced by SARS-CoV-2 infection recognized amongst the infected patients.

show abstract

“…A tonic pupil results from postganglionic parasympathetic pupillomotor denervation, leading classically to mydriasis, poor reaction to light with or without preservation of constriction to accommodation (light-near dissociation), and cholinergic hypersensitivity. Although many cases are idiopathic (Adie tonic pupil), any process which disrupts the postganglionic pupillary fibers can lead to a tonic pupil (1). We present a unique case of bilateral tonic pupils due to the antidisialoganglioside (GD2) chimeric monoclonal antibody, dinutuximab.…”

mentioning

confidence: 99%

Bilateral Tonic Pupils Due to Antidisialoganglioside Antibody Immunotherapy for Neuroblastoma

Swiston¹,

Jebaraj²,

Vegunta³

et al. 2021

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

Adie syndrome

Cited by 3 publications

References 2 publications

Unilateral Adie’s Tonic Pupil after Coronavirus Disease-19 (COVID-19): A Case Report

Unilateral Adie’s Tonic Pupil after Coronavirus Disease-19 (COVID-19): A Case Report

How Does SARS-CoV-2 Affect Our Eyes—What Have We Learnt So Far about the Ophthalmic Manifestations of COVID-19?

Bilateral Tonic Pupils Due to Antidisialoganglioside Antibody Immunotherapy for Neuroblastoma

Contact Info

Product

Resources

About